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Enteropeptidase can cleave trypsinogen on the sequence of Asp-Asp-Asp-Asp-Lys and plays an
important role in food digestion. The RANKL–RANK signalling pathway plays a pivotal role in bone
remodelling. In this study, we reported that enteropeptidase can inhibit the RANKL–RANK signalling
pathway through the cleavage of RANK. A surrogate peptide blocking assay indicated that entero-
peptidase could speciﬁcally cleave RANK on the sequence NEEDK. Osteoclast differentiation assay
and NF-jB activity assay conﬁrmed that enteropeptidase could inhibit osteoclastogenesis in vitro
through the cleavage of RANK. This is the ﬁrst study to prove that the RANKL–RANK signalling path-
way can be inhibited by cleavage of RANK instead of targeting RANKL.
Structured summary of protein interactions:
EP cleaves hRANK by cleavage assay (View interaction)
EP cleaves mRANK by cleavage assay (View interaction)
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction activation by duodenase [1] or trypsin. Trypsinogen is speciﬁcallyEnteropeptidase (EP), a type II transmembrane serine protease
localised to the brush border of the duodenal and jejunal mucosa,
is synthesised as a zymogen (proenteropeptidase), which requirescleaved after the sequence of Asp-Asp-Asp-Asp-Lys, which is
highly conserved in vertebrates. This cleavage results in trypsin-
dependent activation of other pancreatic zymogens, such as chy-
motrypsinogen, proelastase, procarboxypeptidase and prolipase
in the lumen of the gut [2,3]. Diarrhoea, oedema, vomiting, hypo-
proteinaemia, anaemia, and failure to gain weight are common
symptoms of patients with congenital EP deﬁciency during early
infancy [4,5]. Conversely, duodeno-pancreatic reﬂux of proteolyti-
cally active EP can cause acute pancreatitis [6].
EP is a two-chain polypeptide consisting of an N-terminal
120 kDa heavy chain disulphide linked to a C-terminal
47 kDa light chain including a chymotrypsin-like serine prote-
ase domain [7]. The membrane association of the enzyme is not
required for substrate recognition since trypsinogen activation
was not impaired when the transmembrane domain of EP was
deleted. The catalytic capacity of the light chain in the absence
of the heavy chain decreased by approximately 500-fold
compared to the complete EP, suggesting that the heavy chain
is necessary for optimal cleavage. However, the light chain of
EP was sufﬁcient for the normal recognition of substrate target
Y. Zhao et al. / FEBS Letters 587 (2013) 2958–2964 2959sequences [8]. In 1998, Lu and Sadler summarised the features of
substrates required by EP [7]: the substrates of it should contain
Lys/Arg residue at position P1 and four Glu/Asp residues at posi-
tions P2–P5, but more variation is shown at position P5. Receptor
of activator of NF-jB (RANK) is expressed on mammary gland
cells, osteoclast precursors, intestinal epithelial cells and some
cancer cells. There is peptide motif with the sequence Asn-Glu-
Glu-Asp-Lys (NEEDK) (Fig. 1) in the sequence of RANK, which
indicates that RANK may be recognised and cleaved by EP. Since
RANK plays a pivotal role in the differentiation of osteoclasts, we
predicted that EP could inhibit the differentiation of osteoclasts
by cleaving RANK expressed at the surface of osteoclast precur-
sors. There are several inhibitors which could block RANKL–RANK
signalling, such as denosumab [9], an antibody drug approved by
the FDA, OPG-Fc [10], RANK-Fc [11], and peptides that simulate
the interaction between RANKL and RANK [12,13]. However, all
these strategies were based on the blockade of RANKL. By cleav-
age of RANK EP would be the ﬁrst inhibitor for RANK–RANKL sig-
nalling by targeting RANK instead of RANKL.
The aim of this study was to conﬁrm the potential ability of EP
to inhibit osteoclast differentiation by the cleavage of RANK. In this
study, RANK could be efﬁciently cleaved by EP, this was demon-
strated by bands shift on SDS–PAGE. The inhibition effect of osteo-
clast development was demonstrated in a model of osteoclast
differentiation with bone marrow-derived macrophages (BMMs)
in the presence of EP.
2. Materials and methods
2.1. Cell lines, reagents and protein puriﬁcation
The Raw264.7 cell line was purchased from American Type Cul-
ture Collection and propagated in culture according to the manu-
facturer’s protocol. BMMs were isolated from the bone marrow,
which was obtained by ﬂushing femurs and tibiae from 7-wk-old
BALB/c mice as previously reported [14]. Human EP was purchased
from Sigma-Aldrich (St. Louis, MO, USA). The TRAP kit was pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). Anti-RANK
(Ab10498) antibody was purchased from Abcam (Hong Kong, Chi-
na). The rat anti-mouse RANKL mAb (IK22.5) was the gift from Dr.
Hisaya Akiba (Juntendo University, JP). Phenylmethanesulfonyl
ﬂuoride (PMSF) was purchased from MP Biomedical (Santa Ana,
California, USA). Macrophage-colony stimulating factor (M-CSF)
was purchased from eBioscience (San Diego, CA, USA). The Cell
Counting Kit was purchased from Dojindo Laboratories (Kuma-
moto, Japan).The NF-jB luciferase plasmid was the gift from pro-
fessor Xin Ye (Institute of Microbiology, CAS, China).
Lipofectamine 2000 was purchased from Invitrogen (Carlsbad,
CA, USA).The SuperSignal West Pico Trial Kit was purchased from
Thermo (Rockford, USA). The puriﬁcations of recombinant human
RANK, mouse RANK and mouse RANKL were performed as previ-
ously reported [14,15]. TNFRSF18 was prepared by our laboratory
using standard E coli expression system.Fig. 1. Sequence alignment of the extracellular2.2. The synthesis of a surrogate peptide
A surrogate peptide of RANK, DTWNEEDKCLL was synthesised
on 4-MeBHA-resin using manual ‘in situ neutralisation’ Boc chem-
istry protocols for stepwise SPPS[16]. Boc amino acids were used
with the following side chain protection: Asp(OcHxl), Asn(Xan),
Glu(OcHxl), Cys(4-CH3Bzl), Lys(2C1-Z), Thr(Bzl), Glu(OcHex),
Trp(CHO). Other amino acids were used side chain unprotected.
The synthesis was carried out on a 0.25 mmol scale. Prior to HF
deprotection and cleavage, the CHO group of the residue Trp was
removed from the resin-bound peptide segment by treatment with
10% v/v piperidine plus 5% v/v water in DMF for 2 h at 0 C. After
removal of the N-aBocgroup, the peptide was cleaved from the re-
sin and simultaneously deprotected by treatment at 0 C for 1 h
with anhydrous HF containing 5%v/v p-cresol as scavenger. After
removal of HF by evaporation under reduced pressure, the crude
peptide was precipitated and washed with diethyl ether, then dis-
solved in 50% aqueous acetonitrile containing 0.1% TFA and lyoph-
ilised. Analytical RP-HPLC was performed on a Shimadzu LC-15C
system with a C-18 silica column (4.6  250 mm, Venusil
ASB150 Å, 5 lm, Bonna-Agela Technologies, China) at ﬂow rate of
1 ml/min. The peptide was eluted from the column using a gradi-
ent of acetonitrile/0.08% TFA (solvent A) versus water/0.1% TFA
(solvent B). Preparative HPLC of the crude peptide after SPPS was
performed on Shimadzu LC-15C system on aVenusil ASB C-18
(250  10 mm, 150 Å, 5 lm, Bonna-Agela Technologies, China)
column.
2.3. RANK cleavage assay
Recombinant mouse, human RANK, and the mixture of recom-
binant mouse RANK and RANKL at different ratios were incubated
with different concentrations of EP at 37 C for six hours. Recombi-
nant mouse RANK and EP were incubated with PMSF at 37 C for
six hours. TNFRSF18 was treated at the same conditions. Different
concentrations of the surrogate peptide were added into the mix-
ture of mouse RANK and EP then incubated at 37 C for six hours.
All the samples were detected by SDS–PAGE. The recombinant
mouse RANK was incubated with or without EP at 37 C for six
hours, and the samples were detected by Western blotting. All pro-
teins, proteases and peptide above were dissolved in PBS.
2.4. Differentiation of BMMs
BMMs were cultured in a-MEMmedia containing 10% foetal bo-
vine serum (FBS) and 25 ng/ml M-CSF with different concentra-
tions of EP at a density of 1  105 cells per well in a 24-well
culture plate. After adding EP for 1 day, 20 ng/ml mouse RANKL
was added to each well except for the control and the EP alone
group. The media with fresh growth factors was changed every
two days. Ten days later, the cells were ﬁxed and stained for tar-
trate-resistant acid phosphatase (TRAP). Surrogate peptidedomain of RANKs from different species.
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tioned above. The cells with the same treatment as above were
used to quantify TRAP activity as previously described [12]. Brieﬂy,
Naphthol AS phosphate substrate in 100 mM sodium acetate (pH
5.2) reacted with substrates at 37 C for 30 min, and the reaction
product was then quantiﬁed by spectroscopic measurement at
405 nm. Each experiment was repeated four times for statistical
analysis.
2.5. Cell survival assay
The toxicity of EP to BMMs was assessed by Cell Counting Kit-8
assay as previously reported [17]. Brieﬂy, BMMs were cultured at a
density of 5  104 cells per well in 100 ll mediain a 96-well plate.
One day later, different concentrations of EP (0, 0.2, 0.5, 1 lg/ml)
were added to each well except for the blank control wells, which
contained the media. After incubation for 2 days, the media was re-
moved, and the cells were washed twice with fresh media. Then,
100 ll of fresh serum-free a-MEM containing 1/10 (v/v) Cell
Counting Kit-8 reagent was added to each well and incubated for
an additional 4 hours. After incubation, the viability of BMMs
was measured with Cell Counting Kit-8 using a 96-well plate read-
er (DG5032, Huadong, Nanjing, China) at 450 nm. The group with-
out EP served as a negative control. Toxicity was assessed by cell
survival rate (optical density of the treated cells minus the OD of
the blank control)/(OD of negative control minus the OD of the
blank control)  100%).
2.6. Transfection of NF-jB reporter plasmid and the measurement of
luminescence
RAW264.7 cells were transfected with NF-jB luciferase plasmid
with lipofectamine 2000 according to the manufacturer’s protocol.
After 48 hours, transfected cells were divided into 24-well culture
plates at the density of 1x105. 24 hours later, the cells were trans-
ferred in the medium containing mouse RANKL (50 ng/ml) and
incubated for 8 h. The luminescence was measured as previously
described[18]. Brieﬂy, 0.5% NP40 dissolved in PBS was added into
the well for the preparation of cell lysates, and the cells were
scraped from dishes. The supernatant was obtained through the
centrifugation at 13000 rpm for 2 min. 50 ll of supernatant was
placed into wells of an opaque black 96-well plate and an equal
volume of luciferin was added into each well. Then luminescence
was measured by Synergy TM H4 Multi-mode Microplate Reader
(Biotek).
2.7. Western blotting
Prior to Western blotting, 5  104 RAW264.7 cells were cul-
tured in each well of a 24-well culture plate and stimulated by
25 ng/ml M-CSF and 20 ng/ml mouse RANKL for two days. Differ-
ent concentrations of EP were added to the wells and incubated
for ten hours. The cell lysates were subjected to 10% SDS–PAGE
andWestern blotting. The signal was detected by SuperSignal West
Pico Trial Kit.
3. Results
3.1. RANK can be speciﬁcally cleaved by EP
Recombinant mouse RANK was incubated with different con-
centrations of EP at 37 C for six hours. SDS-PAGE analysis showed
that mouse RANK was speciﬁcally cleaved in the presence of
different concentrations of EP, by contrast there was no cleavage
on mouse RANK when thrombin, a different serine protease waspresent (Fig. 2A). Higher concentrations of EP yielded more pro-
found cleavage. Based on the features of substrates required by
EP, only one potential cleavage site, NEEDK, exists in the sequence
of RANK (Fig. 1) and thus the expected cleavage fragment is about
19 kD. The analysis of SDS–PAGE showed that a digested band ap-
peared around 19 kD (shown by arrow, Fig. 2A), which matched
with an expected size. However more bands could also be seen be-
low the expected band, which might be due to that the protein be-
comes more vulnerable to enzyme degradation after being
digested and the conformation destroyed. Recombinant human
RANK could also be speciﬁcally cleaved by EP under the same con-
ditions (Fig. 2B). The 19 kDa of fragment observed byWestern blot-
ting further proved that the cleavage of RANK by EP would happen
at the site of NEEDK sequence (Fig. 2C).
Since RANKL and RANK bind to each other, it is worthy of con-
sideration whether RANKL plays a protective role in the process of
cleavage. In this study, different mass ratios (1:0, 1:1, 1:2, 1:4) of
RANK and RANKL were used to test the potential of protective ef-
fect of RANKL. In the group of 1:0, RANK was clearly cleaved. With
increased concentrations of RANKL, the cleavage effects were
weakened but still present (Fig. 2D). These results implied that
RANKL had a limited protective effect on the EP-mediated cleavage
of RANK.
Since EP is a serine protease, we attempted to block its activity
with PMSF, a serine protease inhibitor, to conﬁrm that cleavage
was EP-dependent. Mouse RANK was incubated with EP, a mixture
of EP and PMSF, PMSF alone or nothing. The results of SDS–PAGE
analysis demonstrated that RANK could be cleaved only in the EP
group (Fig. 2E). These results suggested that the digestion was spe-
ciﬁcally mediated by EP.
To conﬁrm the speciﬁcity of the EP-dependent cleavage, we
used TNFRSF18, another member of tumour necrosis factor recep-
tor superfamily (TNFRSF) as a control. Since there is no substrate
motif presented in TNFRSF18 for EP we expected that there would
be no cleavage on TNFRSF18 by EP. After incubation of TNFRSF18
with EP for 2 h at 37 C, SDS–PAGE was carried out and subjected
to Coomassie brilliant blue staining to demonstrate the cleavage.
As expected, TNFRSF18 was not cleaved while RANK was clearly
broke down by EP (Fig. 2F).
To further prove that the digestion site was on the sequence of
NEEDK, we designed a surrogate peptide, DTWNEEDKCLL corre-
sponding to residues 78-88 of mouse RANK and containing the pre-
dicted cleavage amino acids. Recombinant mouse RANK was
incubated with EP along with different concentrations of peptides
at 37 C for six hours. SDS–PAGE analysis showed that the surro-
gate peptide could compete with mouse RANK and protected RANK
from being digested by EP in a dose-dependent manner (Fig. 2G).
The data indicates that the sequence NEEDK was the speciﬁcally
cleavage site on RANK by EP.
3.2. EP can block the differentiation of BMMs into osteoclasts
BMMs were isolated from bone marrow that was obtained by
ﬂushing femurs and tibiae from 7-wk-old BALB/c mice, and the dif-
ferentiation assay was carried out to assess the ability of EP to in-
hibit the differentiation of BMMs. All the groups of BMMs were
cultured in a-MEM media with 25 ng/ml M-CSF. The control group
was cultured without EP, while the EP group was cultured with
200 ng/ml EP. The osteoclasts were observed after the staining of
TRAP. There were no TRAP staining-positive cells or mature osteo-
clasts (TRAP staining-positive, multinuclear cells with diame-
ter > 100 lm) formed in either group. Extra two groups were
cultured in a-MEM media containing 50 ng/ml mouse RANKL with
or without 200 ng/ml EP. The cells in the group without EP clearly
differentiated, and the number of mature osteoclasts was
Fig. 2. Cleavage of hRANK and mRANK by EP. Recombinant mouse (A) or human (B) RANK (0.8 mg/ml) was incubated with different concentrations of EP or 1 lg/ml thrombin
at 37 C for 6 h. The samples were loaded onto a 15% SDS–PAGE gel, and the gel was stained with Coomassie brilliant blue. RANK (0.2 mg/ml) was incubated with EP (1 lg/ml)
at 37 C for 6 hours and then subjected to Western blotting (C). (D) RANKL had a limited protective effect from the cleavage of RANK by EP. mRANK (0.2 mg/ml) was mixed
with mRANKL in different mass ratio (1:0, 1:1, 1:2 and 1:4, room temperature for 15 min) and then the mixtures were incubated with 1 lg/ml EP at 37 C for 6 h. (E) PMSF
could block the cleavage of RANK mediated by EP. mRANK (0.8 mg/ml) was incubated with or without 3 lg/ml EP or 1 mM PMSF. (F) RANK (0.8 mg/ml) and TNFRSF18
(0.5 mg/ml) were incubated with or without 1 lg/ml EP at 37 C for 6 h. The samples were loaded onto a 15% SDS–PAGE gel, and the gel was stained with Coomassie brilliant
blue. (G) Recombinant mouse RANK (0.15 mg/ml) was incubated with 0.1 lg/ml EP and different concentrations of surrogate peptide at 37 C for 6 h. The samples were
loaded onto a 15% SDS–PAGE gel, and the gel was stained with Coomassie brilliant blue.
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positive cells and no mature osteoclasts (Fig. 3A and B).
We further measured the TRAP activity of the BMMs under con-
ditions of different EP concentrations by spectroscopic measure-
ment at 405 nm. The control group was cultured without EP or
mouse RANKL, while the other groups were cultured with 20 ng/
ml mouse RANKL and EP at different concentrations. With de-
creased concentrations of EP, the TRAP activity increased. The TRAP
activity of the group cultured with 400 ng/ml EP was similar to the
control group. Meanwhile, after the removal of the background va-
lue, the TRAP activity of the group cultured without EP was
approximately ﬁfty-fold higher compared to the group cultured
with 200 ng/ml EP (Fig. 3C).To conﬁrm that the differentiation inhibition was not due to
toxicity of EP, the Cell Counting Kit-8 assay was performed. EP
exhibited little toxicity to the BMMs in high concentration groups
(1, 0.5 lg/ml), in which the survival rates were 96 and 98%, and no
toxicity at the low concentration (0.2 lg/ml), which was the work-
ing concentration for the differentiation assay (Fig. 3D). These re-
sults indicated that there was not a link between the inhibition
effect of EP and its toxicity to BMMs.
To demonstrate downstream NF-jB pathway was affected
when RANK was digested by EP enzyme, we transfected NF-jB
luciferase report plasmid into RAW264.7 cells and monitor the
activation of NF-jB signalling to conﬁrm that the inhibition of
osteoclastogenesis by EP was achieved by the cleavage of RANK.
Fig. 3. Inhibition of osteoclast differentiation mediated by EP. (A) The control group was cultured in media without EP or RANKL. The group cultured in the presence of 50 ng/
ml RANKL contained many multinucleated, large diameter (>100 lm) TRAP staining-positive cells. The group cultured in media both EP (200 ng/ml) and RANKL (50 ng/ml)
contained few incompletely differentiated, TRAP staining-positive and small diameter cells. The group cultured in the presence of 200 ng/ml EP did not contain differentiated
cells. All the groups were cultured with 25 ng/ml M-CSF. Scale bar, 300 lm. (B) The multinucleated, TRAP staining-positive and large diameter (>100 lm) cells were counted.
The bar represents the average of four independent experiments, and the data were shown as the mean ± S.D. ⁄⁄P < 0.01. (C) TRAP activity of the BMMs cultured with different
concentrations of EP. All the groups were cultured in a-MEM media containing 25 ng/ml M-CSF. The control group was cultured without RANKL and EP, while the other
groups were cultured with 20 ng/ml RANKL and different concentrations of EP. The curve represents the average of four independent experiments with S.D. bars. (D)
Cytotoxicity assay for BMMs cultured with different concentrations of EP. The negative control was untreated cells, and the blank control contained the Cell Counting Kit-8
reagent without cells. The curve represents the average of three independent experiments, and the data were shown as the mean ± S.D. (E) Luciferase activity were presented
as the folds of basal value (control). RAW264.7 cells were transfected with NF-jB luciferase plasmid for 48 hours and then the cells were incubated with 50 ng/ml mouse
RANKL for 8 hours. Then the luminescence was measured. Each group was repeated for four times. The data were shown as the mean ± S.D. ⁄P < 0.05. (F) The control group
was cultured with or without RANKL, EP or peptide. The concentrations of EP, mouse RANKL and peptide were 200 ng/ml, 50 ng/ml and 0.2 mg/ml respectively. All the groups
were cultured with 25 ng/ml M-CSF. Scale bar, 300 lm. (G) The multinucleated, TRAP staining-positive and large diameter (>100 lm) cells were counted. The bar represents
the average of four independent experiments, and the data were shown as the mean ± S.D. ⁄⁄⁄P < 0.001. (H) TRAP activity of the BMMs cultured in the same condition as that
shown on Fig. 3F. The colomn represents the average of four independent experiments with S.D. bars. ⁄⁄P < 0.01.
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As shown in Fig. 3E, the activity of NF-jB in the RANKL group, was
about 3-fold of the group with EP added and the group with anti-
RANKL antibody. The activity of NF-jB of the RANKL group was
close to the EP and surrogate group (Fig. 3E).These results indicate
that EP can inhibit RANKL-induced NF-jB activation.We further tested whether the surrogate peptide could inhibit
the effect of EP on RANK by BMM differentiation assay. There
was no differentiated cell in the EP group when the cells were cul-
tured with mouse RANKL in the presence of EP. While in the group
cultured with mouse RANKL in the presence of both EP and the
peptide, there was a similar number of differentiated cells
Fig. 4. Western blotting of RANK expression on the surface of RAW264.7 cells. After cleavage by EP, Western blotting was performed to estimate the cleavage effect. In the
400 and 200 ng/ml groups, two bands could be clearly seen.
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cultured with RANKL and peptide (Figs. 3F and G). We have also
measured the TRAP activity of the BMMs treated as mentioned
above. The TRAP activities of control group and the peptide alone
group were almost the same. The group cultured with RANKL, EP
and the peptide had a little lower TRAP activity compared with
that in the group cultured with RANKL and RANKL plus peptide
group (Fig. 3H). These results together suggested that the inhibi-
tion of osteoclastogenesis by EP was achieved through the cleavage
of RANK.
3.3. Cleavage of RANK expressed on the cell membrane by EP
After the cleavage of RANK by different concentrations of EP,
Western blotting was performed to estimate the cleavage effect.
We used RAW264.7 cells, a murinemacrophage-likecell line with
high levels of RANK expression, to examine the cleavage of mem-
brane bound RANK by Western blotting. As shown in Fig. 4, it
was showed that anti-RANK antibody could speciﬁcally detect in-
tact RANK and digested RANK expressed on RAW264.7 cells, while
could not detect this protein on K41, a wild-type mouse embryonic
ﬁbroblasts cell line used as a RANK-expression negative control.
With decreased concentrations of EP, the cleavage effect became
weaker. EP at the concentrations of 200 and 400 ng/ml had a signif-
icant cleavage effect for the RANK expressed on cells was cleaved
into two visible segments.
4. Discussion
In this study, we showed that EP had the ability to cleave RANK
on the sequence NEEDK. By contrast, thrombin, a different serine
protease without ability to cleave NEEDK sequence failed to cleave
RANK, and EP could not cleave TNFRSF18, another member of
TNFRSF without NEEDK sequence. Moreover, PMSF could block
the ability of EP to cleave RANK. A surrogate peptide of RANK could
protect RANK from being digested by EP. In the NF-jB activation
assay, NF-jB signalling could be blocked by EP by the cleavage of
RANK. Similarly, in the BMM differentiation assay, the surrogate
peptide could rescue RANKL-induced osteoclastogenesis. These re-
sults showed that the cleavage of RANK was effective and speciﬁc.
As shown in Fig. 1, RANKs from different mammals (human,
mouse, rat, rabbit, and gorilla) contain the NEEDK sequence. There-
fore, we predicted that RANKs of various species could be cleaved
by EP. In deed, both mouse and human RANK could be cleaved by
EP (Fig. 2A and 2B).
There are several inhibitors available for RANKL-RANK signal-
ling pathway for instance, OPG-Fc, RANK-Fc, the human monoclo-
nal antibody denosumab. These inhibitors all interfere with
RANKL-RANK signalling through the blockade of RANKL. Here we
have described EP, a novel inhibitor of the RANKL–RANK signalling
by the cleavage of RANK. We believe that this is the ﬁrst time todemonstrate that the RANK can be used as a target to block
RANKL–RANK signalling. Furthermore, EP has been proved to be
effective for inhibiting RANK functions in vitro and would be a use-
ful tool for osteoclastogenesis-related research.
The classical substrate sequence for EP recognition is (E/D)4-K.
RANKs from different species have the NEEDK sequence, which is a
little different from the classical recognition sequence. However,
based on the features of the substrates that EP can recognise, we
predicted that RANK could be recognised and cleaved. In deed as
predicted, RANK could be cleaved by EP. A weaker cleavage was ex-
pected, due to the non-classical sequence in RANK. Although
NEEDK sequence is not an ideal substrate sequence, the inhibition
of BMM differentiation was not affected.
As we reported previously, residues Glu84 and Asp85 of RANK
in the sequence NEEDK (mouse residue 81-86), play an important
role in the interaction of RANKL and RANK [14]. We examined the
cleavage of RANK in the presence of RANKL to determine whether
RANKL had a protective effect. Our results show that, although
RANKL and RANK could form a heterotrimer complex, EP could rec-
ognise the sequence and cleave RANK in a weaker manner. The
three-dimensional steric hindrance may have given rise to the
weaker cleavage.
The RANK-cleavage activity of EP presented in our study sug-
gests a possible application of this enzyme in the treatment of dis-
eases. The RANKL–RANK signalling pathway plays a pivotal role in
regulating osteoclast development and function. Therefore, this
pathway is demonstrated to be a good target for treatments of oste-
oporosis, tumour bone metastases and other diseases associated
with bone loss. We speculate that EP would be a potential treat-
ment for bone loss related diseases since it could block osteoclast
differentiation. The supposition needs to be tested in future trials.
Moreover, the cleavage activity of EP may provide a clue to its
potential roles in the development of diseases. EP is reported to
be expressed at the surface of prostate cancer cells [19]. We
hypothesize it may contribute to the formation of osteoblastic le-
sions at the early stage of prostate cancer bone metastases through
the inhibition of RANKL–RANK signalling pathway. Besides, duode-
no-pancreatic reﬂux of proteolytically active EP can cause acute
pancreatitis [6], which gives rise to the impairment of mucosal
immunity and a decreased concentration of secretary IgA (SIgA).
This is the primary reason for bacterial and endotoxin transloca-
tion [20]. In 2009, Kathryn A. Knoop et al. reported that the
RANKL-RANK pathway controls the differentiation of micro-fold
cells (M cells), the antigen transporters to T cells that support B cell
activation, from RANK-expressing intestinal epithelial precursor
cells [21]. We hypothesize that during acute pancreatitis, EP
cleaves not only trypsinogen but also RANK expressed on the sur-
face of epithelial precursor cells. This may cause the inhibition of M
cell differentiation. Furthermore, the lack of M cells may inhibit B
cell activation and cause a decrease in SIgA. These hypotheses re-
quire further investigation.
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